The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | Updated results of Phase I/II BRUIN study: pirtobrutinib in covalent BTK inhibitor pretreated MCL
Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, shares the three-year follow-up results of a subgroup analysis of the Phase I/II BRUIN study (NCT03740529) evaluating pirtobrutinib in patients with mantle cell lymphoma (MCL) who have been treated with covalent BTK inhibitors. The long-term follow-up results show high and durable responses, with a low rate of severe adverse events and BTK inhibitor-associated adverse events across all MCL subgroups. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
